ClinicalTrials.gg
CompletedNCT06588504Updated Nov 16, 2026Results posted

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

A Phase 3 interventional study of Dasiglucagon and Glucagon in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Updated Nov 16, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. dasiglucagon · Diabetes Mellitus, Type 1.

Enrollment
5th of 12
38 · median 31
Started
2024
the only one that year
Phase 3
6 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Novo Nordisk A/S

Among the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 12th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About dasiglucagon

dasiglucagon: first FDA approval 2021 (ZEGALOGUE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing dasiglucagon in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low blood sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D. This study wants to demonstrate that dasiglucagon can raise low blood sugar levels just as well as glucagon. Participants will get dasiglucagon and glucagon. In which treatment order participants get study medicines (dasiglucagon and glucagon) is decided by chance. Dasiglucagon is a new medicine, but doctors can prescribe it in the US as it is approved there. Doctors can prescribe glucagon in multiple countries including Japan as an approved medicine. The study will last for about 17 weeks. Participant cannot be in the study if the study doctor thinks that there are risks for participants health. Women cannot take part if pregnant, breast-feeding, plan to get pregnant, during the study period, or not using adequate contraceptive methods. For man: if participant have sex, participant and his partner must use an adequate birth control method during the study.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Adults: Asian male or female; For Adolescents: Japanese male or female.
  • Age at the time of signing the :

For Adults: Age 18-75 years (both inclusive):

For Adolescents: Age 12-15 years (both inclusive).

  • Diagnosed with T1D greater than (>)1 year before screening.
  • (HbA1c) less than (\<)10.0 percentage (%) (86 millimoles per mole [mmol/mol]) as assessed by subcontracted laboratory by the site on the day of screening.
  • For adults: between 18.5 and 29.9 kilogram per meter square (kg/m2) (both inclusive).

For adolescents: Body weight greater than or equal to (≥) 33.4 kilograms (kg).

  • Treated with stable insulin treatment (based on the investigator's discretion preferably no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening.
  • For Japanese participants: Japanese passport or equivalent For non-Japanese participants: Asian (non- Japanese passport or equivalent).

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products (glucagon or its derivatives).
  • Exposure to an medicinal product (IMP) within 30 days or 5 times the half-life of the IMP (if known), whichever is longest before screening.
  • Severe hypoglycaemia in the last month prior to screening.
  • Hospitalisation for diabetic ketoacidosis (DKA) in the last month prior to screening.
  • Presence or history of any respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus).
  • History of epilepsy or seizure disorder.
  • Known presence or history of pheochromocytoma (i.e., adrenal gland tumour) or insulinoma (i.e., insulin-secreting pancreas tumour).
  • Clinically significant abnormal (ECG) at screening as evaluated by investigator.
  • Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.

As declared by the participant or in the medical records.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Adult Cohort: Dasiglucagon then Glucagon

    Participants will receive a single subcutaneous (s.c.) injection of dasiglucagon in first dosing visit then a single intra-mascular (i.m.) injection of glucagon in next dosing visit.

    Drug: Dasiglucagon

  • Experimental
    Adult Cohort: Glucagon then Dasiglucagon

    Participants will receive a single i.m. injection of glucagon in first dosing visit then a single s.c. injection of dasiglucagon in next dosing visit.

    Drug: Dasiglucagon · Drug: Glucagon

  • Experimental
    Adolescent Cohort: Dasiglucagon

    Participants will receive a single s.c. injection of dasiglucagon.

    Drug: Dasiglucagon

Interventions

  • Participants will receive s.c. injection of dasiglucagon.

  • Participants will receive i.m. injection of glucagon.

06

What researchers measure

Primary outcomes

  1. Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline

    This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter \[mmol/L\]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.

    Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection

Secondary outcomes

  1. Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)

    This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.

    Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection

  2. Number of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)

    This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

    Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection

  3. Number of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)

    This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

    Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection

  4. Number of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)

    This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

    Time frame: Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection

  5. Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection

    This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms.

    Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection

  6. Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection

    This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms.

    Time frame: Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection

  7. AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection

    This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms.

    Time frame: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)

  8. Cmax: Maximum Observed Plasma Dasiglucagon Concentration

    This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms.

    Time frame: Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)

  9. Number of Adverse Events (AEs) for All Participants in Each Arms

    This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP.

    Time frame: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection

  10. Number of Hypoglycaemic Episodes for All Participants in Each Arms

    This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); \<3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; \< 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery.

    Time frame: From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.

07

Results

Posted Nov 16, 2026

Participant flow

The study was conducted at 1 site in Japan.

Overall Recruitment
Participant flow — Overall Recruitment
MilestoneGlucagon/Dasiglucagon (Adults)Dasiglucagon/Glucagon (Adults)Dasiglucagon (Adolescents)
Started17174
Exposed to investigational medicinal product (imp)16174
Full analysis set (fas)16174
Safety analysis set (sas)16174
Completed16174
Not completed100
Withdrew: Physician decision100
First Intervention
Participant flow — First Intervention
MilestoneGlucagon/Dasiglucagon (Adults)Dasiglucagon/Glucagon (Adults)Dasiglucagon (Adolescents)
Started16174
Completed16174
Not completed000
Washout Period 1
Participant flow — Washout Period 1
MilestoneGlucagon/Dasiglucagon (Adults)Dasiglucagon/Glucagon (Adults)Dasiglucagon (Adolescents)
Started16170
Completed16170
Not completed000
Second Intervention
Participant flow — Second Intervention
MilestoneGlucagon/Dasiglucagon (Adults)Dasiglucagon/Glucagon (Adults)Dasiglucagon (Adolescents)
Started16170
Completed16170
Not completed000

Outcome measures

PrimaryTime to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline

This outcome measure reported time to PG recovery in Asian Japanese adults. PG recovery was defined as the first increase in PG of greater than or equal to (≥) 20 milligrams per deciliter (mg/dL) (1.1 millimoles per liter \[mmol/L\]) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.

Time frame:
Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
Reported as:
Mean · Minutes
Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline
MinutesDasiglucagon (Adults)Glucagon (Adults)
Time to Plasma Glucose (PG) Recovery in Adults: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline8.72 ± 1.908.16 ± 1.68
Statistical analysis
  • Dasiglucagon (Adults) vs Glucagon (Adults) · Treatment difference: 0.58 · 95% CI 0.03 to 1.14
SecondaryTime to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)

This outcome measure reported time to PG recovery in adolescents Japanese population. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline. Time to PG recovery was derived using linear interpolation between the last observed time point before recovery and the first observed time point after recovery, based on actual sampling time points with time zero as time of IMP injection.

Time frame:
Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
Reported as:
Mean · Minutes
Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)
MinutesDasiglucagon (Adolescents)
Time to Plasma Glucose Recovery in Adolescents: First Increase in PG of ≥20 mg/dL (1.1 mmol/L) From Baseline (Japanese Adolescent Cohort Only)7.22 ± 0.87
SecondaryNumber of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)

This outcome measure reported number of participants achieving PG recovery within 30 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

Time frame:
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
Reported as:
Count of participants · Participants
Number of Participants Achieving PG Recovery Within 30 Minutes After IMP Injection (Yes/No)
ParticipantsDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Yes33334
No000
SecondaryNumber of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)

This outcome measure reported number of participants achieving PG recovery within 20 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

Time frame:
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
Reported as:
Count of participants · Participants
Number of Participants Achieving PG Recovery Within 20 Minutes After IMP Injection (Yes/No)
ParticipantsDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Yes33334
No000
SecondaryNumber of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)

This outcome measure reported number of participants achieving PG recovery within 15 minutes after IMP injection in adults and adolescents population arms, in terms of 'Yes' and 'No'. PG recovery was defined as the first increase in PG of ≥20 mg/dL (1.1 mmol/L) from baseline.

Time frame:
Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
Reported as:
Count of participants · Participants
Number of Participants Achieving PG Recovery Within 15 Minutes After IMP Injection (Yes/No)
ParticipantsDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Yes33334
No000
SecondaryChange From Baseline in Plasma Glucose at 15 Minutes After IMP Injection

This outcome measure reports change from baseline in plasma glucose at 15 minutes after IMP injection for all participants in adults and adolescents arms.

Time frame:
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
Reported as:
Mean · mg/dL
Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection
mg/dLDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Change From Baseline in Plasma Glucose at 15 Minutes After IMP Injection48.09 ± 14.3851.21 ± 11.7251.50 ± 4.51
SecondaryChange From Baseline in Plasma Glucose at 20 Minutes After IMP Injection

This outcome measure reports change from baseline in plasma glucose at 20 minutes after IMP injection for all participants in adults and adolescents arms.

Time frame:
Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
Reported as:
Mean · mg/dL
Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection
mg/dLDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Change From Baseline in Plasma Glucose at 20 Minutes After IMP Injection63.35 ± 17.0765.30 ± 13.3869.00 ± 9.02
SecondaryAUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection

This outcome measure reported area under the plasma dasiglucagon concentration (AUC) time curve using the linear trapezoidal technique based on observed values and actual measurement times from 0 to 30 minutes (AUC0-30min) after IMP injection was administered in adult and adolescent participants in each reported arms.

Time frame:
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
Reported as:
Geometric mean · h*pmol/L
AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection
h*pmol/LDasiglucagon (Adults)Dasiglucagon (Adolescents)
AUC0-30min: Area Under the Plasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP Injection346.39 ± 46.22NA ± NA
SecondaryCmax: Maximum Observed Plasma Dasiglucagon Concentration

This outcome measure reported maximum observed plasma dasiglucagon concentration (Cmax) after IMP injection was administered in adult and adolescent participants in each reported dasiglucagon arms.

Time frame:
Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
Reported as:
Geometric mean · pmol/L
Cmax: Maximum Observed Plasma Dasiglucagon Concentration
pmol/LDasiglucagon (Adults)Dasiglucagon (Adolescents)
Cmax: Maximum Observed Plasma Dasiglucagon Concentration1230.24 ± 33.47NA ± NA
SecondaryNumber of Adverse Events (AEs) for All Participants in Each Arms

This outcome measure reported Number of adverse events (AEs) for all participants in adults and adolescents arms. An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP.

Time frame:
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
Reported as:
Number · Events
Number of Adverse Events (AEs) for All Participants in Each Arms
EventsDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Number of Adverse Events (AEs) for All Participants in Each Arms29183
SecondaryNumber of Hypoglycaemic Episodes for All Participants in Each Arms

This outcome measure reports number of hypoglycaemic episodes for all participants in adults and adolescents arms. Hypoglycaemic episode is measured in terms of PG (blood or urine ketones were measured). Hypoglycaemia is defined as a decline in PG to below 70 mg/dL (3.9 mmol/L). Classification of hypoglycaemia (Level; Glycaemic criteria; Description) are as follows: 1) - Hypoglycaemia alert value (level 1); \<3.9 mmol/L (70 mg/dL) and ≥3.0 mmol/L (54 mg/dL); Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy. 2) Clinically significant hypoglycaemia; \< 3.0 mmol/L (54 mg/dL); Sufficiently low to indicate serious, clinically important hypoglycaemia (level 2). 3) Severe hypoglycaemia (level 3); No specific glucose threshold; Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery.

Time frame:
From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
Reported as:
Number · Episodes
Number of Hypoglycaemic Episodes for All Participants in Each Arms
EpisodesDasiglucagon (Adults)Glucagon (Adults)Dasiglucagon (Adolescents)
Hypoglycaemia alert value (level 1)020
Clinically significant hypoglycaemia (level 2)011
Severe hypoglycaemia (level 3)100
Severe (level 3) or clinically significant (level 2) hypoglycaemia111

Adverse events

Collected over From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glucagon (Adults)0/33 (0%)0/33 (0%)9/33 (27.3%)
Dasiglucagon (Adults)0/33 (0%)0/33 (0%)16/33 (48.5%)
Dasiglucagon (Adolescents)0/4 (0%)0/4 (0%)2/4 (50%)
Total0/37 (0%)0/37 (0%)21/37 (56.8%)
Most frequent other events
Most frequent other events
EventGlucagon (Adults)Dasiglucagon (Adults)Dasiglucagon (Adolescents)Total
NauseaGastrointestinal disorders9/3315/332/420/37
VomitingGastrointestinal disorders8/3313/331/416/37
DiarrhoeaGastrointestinal disorders1/331/330/42/37

Baseline characteristics

Baseline analysis was conducted on FAS population. FAS (adults)-All randomized adult participants who received at least one dose of IMP; FAS (adolescents)-All adolescent participants who received one dose of IMP.

Age, Continuous
Age, Continuous(Years)Dasiglucagon and Glucagon (Adults)Dasiglucagon (Adolescents)Total
Mean40.03 ± 11.6613.75 ± 0.9637.2 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Dasiglucagon and Glucagon (Adults)Dasiglucagon (Adolescents)Total
Female12214
Male21223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dasiglucagon and Glucagon (Adults)Dasiglucagon (Adolescents)Total
Hispanic or Latino000
Not Hispanic or Latino33437
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dasiglucagon and Glucagon (Adults)Dasiglucagon (Adolescents)Total
American Indian or Alaska Native000
Asian33437
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Hakata Clinic
    Fukuoka, 812-0025, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jul 2025, 10 months.

Results were first posted in Nov 2026, 1 year 3 months after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 10 months is below that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Sep 10, 2024
Primary completionActual
Jul 20, 2025
CompletionActual
Jul 20, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAdults cohort: Time to plasma glucosePlasma Glucose (PG) recovery, where PG recovery is defined as the first increaseRecovery in Adults: First Increase in PG of greater than or equal to (>=) ≥20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baselineFrom BaselineTime frame: From 0 to 90 minutes after investigational medicinal product (IMP) injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
Nov 16, 2026
Documents
Secondary outcomes
10 edited
What changed in the outcomes
  • EditedAdolescent cohort: Time to PG recovery, where PG recovery is defined as the first increasePlasma Glucose Recovery in Adolescents: First Increase in PG of >=≥20 mg/dL (1.1 mmol/L) from baselineFrom Baseline (Japanese Adolescent Cohort Only)Time frame: From 0 to 90 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
  • EditedNumber of Participants Achieving PG recovery withinRecovery Within 30 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 30 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
  • EditedNumber of Participants Achieving PG recovery withinRecovery Within 20 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 20 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
  • EditedNumber of Participants Achieving PG recovery withinRecovery Within 15 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 15 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
  • EditedPG change from baselineChange From Baseline in Plasma Glucose at 15 minutes afterMinutes After IMP injectionInjectionTime frame: From 0 to 15 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
  • EditedPG change from baselineChange From Baseline in Plasma Glucose at 20 minutes afterMinutes After IMP injectionInjectionTime frame: From 0 to 20 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
  • EditedAUC0-30min: Area underUnder the plasma dasiglucagon concentration time curve afterPlasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP injectionInjectionTime frame: On Day 1 after injection → Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
  • EditedCmax: Maximum observed plasma (Cmax) dasiglucagon concentrationObserved Plasma Dasiglucagon ConcentrationTime frame: From 0 to 5 hours after IMP injection → Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
  • EditedNumber of adverse eventsAdverse Events (AEs) for All Participants in Each ArmsTime frame: From IMP injection (visit 2 day 1 and visit 3 day 1) until 28 days after IMP injection → From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
  • EditedNumber of hypoglycaemic episodesHypoglycaemic Episodes for All Participants in Each ArmsTime frame: From IMP injection (visit 2 day 1 and visit 3 day 1) until 12 hours after IMP injection → From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
Nov 16, 2026
Design
Phase 1→Phase 3
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAdults cohort: Time to plasma glucosePlasma Glucose (PG) recovery, where PG recovery is defined as the first increaseRecovery in Adults: First Increase in PG of greater than or equal to (>=) ≥20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baselineFrom BaselineTime frame: From 0 to 90 minutes after investigational medicinal product (IMP) injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 90 minutes after IMP injection
    Secondary outcomes 10 edited
    What changed in the outcomes
    • EditedAdolescent cohort: Time to PG recovery, where PG recovery is defined as the first increasePlasma Glucose Recovery in Adolescents: First Increase in PG of >=≥20 mg/dL (1.1 mmol/L) from baselineFrom Baseline (Japanese Adolescent Cohort Only)Time frame: From 0 to 90 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1): 0 to 90 minutes after IMP injection
    • EditedNumber of Participants Achieving PG recovery withinRecovery Within 30 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 30 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 30 minutes after IMP injection
    • EditedNumber of Participants Achieving PG recovery withinRecovery Within 20 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 20 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 20 minutes after IMP injection
    • EditedNumber of Participants Achieving PG recovery withinRecovery Within 15 minutes afterMinutes After IMP injectionInjection (yesYes/noNo)Time frame: From 0 to 15 minutes after IMP injection → Visit 2-Day 1 (Day 1) and/or Visit 3-Day 1 (any day between Day 29 to 43): 0 to 15 minutes after IMP injection
    • EditedPG change from baselineChange From Baseline in Plasma Glucose at 15 minutes afterMinutes After IMP injectionInjectionTime frame: From 0 to 15 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 15 minutes after IMP injection
    • EditedPG change from baselineChange From Baseline in Plasma Glucose at 20 minutes afterMinutes After IMP injectionInjectionTime frame: From 0 to 20 minutes after IMP injection → Baseline (Day 1), Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): at 20 minutes after IMP injection
    • EditedAUC0-30min: Area underUnder the plasma dasiglucagon concentration time curve afterPlasma Dasiglucagon Concentration Time Curve From 0 to 30 Minutes After IMP injectionInjectionTime frame: On Day 1 after injection → Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, and 30 minutes (From 0 to 30 minutes after IMP injection)
    • EditedCmax: Maximum observed plasma (Cmax) dasiglucagon concentrationObserved Plasma Dasiglucagon ConcentrationTime frame: From 0 to 5 hours after IMP injection → Visit 2-Day 1 (Day 1) and Visit 3-Day 1 (any day between Day 29 to 43): Predose: 0 minute, Post-dose: 5, 15, 20, 25, 30, 35, 40, 45, 60, 90, 120, 210, 300 minutes (From 0 to 5 hours after IMP injection)
    • EditedNumber of adverse eventsAdverse Events (AEs) for All Participants in Each ArmsTime frame: From IMP injection (visit 2 day 1 and visit 3 day 1) until 28 days after IMP injection → From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 28 days after IMP injection
    • EditedNumber of hypoglycaemic episodesHypoglycaemic Episodes for All Participants in Each ArmsTime frame: From IMP injection (visit 2 day 1 and visit 3 day 1) until 12 hours after IMP injection → From IMP injection administration on Visit 2 Day 1 (Day 1) and/or Visit 3 Day 1 (any day between Day 29 to 43) until 12 hours after IMP injection.
    Design Phase 1→Phase 3
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06588504
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 10, 2024
Primary completion
Jul 20, 2025
Completion
Jul 20, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dasiglucagon

Start the discussion